US Bancorp
ADMS

US Bancorp’s Adamas Pharmaceuticals ADMS Stock Holding History

US Bancorp’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,465
Closed -$41K – 3740
2015
Q3 		$41K Hold
2,465
– – ﹤0.01% 2559
2015
Q2 		$65K Buy
+2,465
New +$47.9K ﹤0.01% 2394

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp's ADMS Position: Q4 2015 in Review

US Bancorp sold out of Adamas Pharmaceuticals (ADMS) in Q4 2015, closing a stake of 2,465 shares — an estimated $41K sold.

US Bancorp first reported a position in ADMS in Q2 2015 and held it in 2 quarters. The position peaked at $65K in Q2 2015. 93 funds tracked by Wall St. Rank hold ADMS as of Q4 2015.

  • US Bancorp reported no remaining Adamas Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • US Bancorp sold 2,465 Adamas Pharmaceuticals shares in Q4 2015, an estimated $41K.
  • US Bancorp first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • US Bancorp's Adamas Pharmaceuticals position peaked at $65K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2015.

Based on US Bancorp's 13F filing for Q4 2015, filed 10 Feb 2016.